US Labor Department finalizes PBM fee disclosure rule for July 2027

DOL finalizes PBM fee disclosure rule

The rule forces pharmacy benefit managers to tell the employers that hire them about every fee and payment they receive from drugmakers, consulting firms and other entities. Disclosures must include drug rebates, spread pricing, and financial relationships with brokers and consultants that could create conflicts of interest.

The practical effect is a paper trail. Employers get the numbers they need to challenge a PBM's bid, and federal officials say the savings should reach workers through lower drug costs. None of that starts before 1 July 2027.

Officials estimate the rule will save more than $800 million a year through lower drug costs. Drug Topics, citing the same announcement, reported a projection of as much as $22 billion in savings over 10 years. The two figures use different horizons, and neither is a guarantee. The DOL issued the rule under ERISA section 408(b)(2)(B). It covers PBMs and service providers earning $1,000 or more.

Compliance opens with written disclosures at least 90 days before a contract signing.

What employers and pharmacies get

The requirements go deeper than one fee line. PBMs must break down spread pricing by individual medication and by pharmacy distribution channel. They must also describe policies that steer patients toward PBM-owned mail-order or specialty outlets. Plan administrators gain annual audit rights over transaction data and drugmaker contracts, not just selective sampling. Independent pharmacies have argued for years that audits and clawbacks hit them unevenly. This hands their clients a way to check.

The National Community Pharmacists Association petitioned the DOL in August 2025 for exactly this kind of ERISA enforcement.

Audits cut both ways. An October 2025 New York State Comptroller report found shortcomings in Caremark's auditing of the Empire Plan, including failures to perform audits the contract required.

The backdrop is grim for many small pharmacies. Drug Topics reported that more than 57 million people live in pharmacy deserts. It also reported that another 28.9 million depend on a single keystone pharmacy whose closure would cut off local access. Pharmacies sometimes lose $80 to $100 on each prescription when they dispense brand-name diabetes and weight-loss drugs. Cash flow adds to the strain: most independent owners wait at least 22 days for manufacturer refunds, and 20% wait more than 28 days.

The same problem repeats inside Medicare's negotiated prices. Allison Schneider of ADVI Health told Drug Topics that pharmacies will need to float thousands of dollars per prescription. That pressure grows in 2027. CMS then adds negotiated prices for 15 more high-cost cancer and chronic disease drugs, covering 5.3 million beneficiaries. Adam Colborn of AMCP expects payment delays through the Medicare Transaction Facilitator to return each January. Independent pharmacies will feel it most.

CAA 2026 sets the underlying rules

The disclosure rule sits on top of a bigger statute. The Consolidated Appropriations Act of 2026 became law on 3 February 2026. It eliminates spread pricing for PBMs. It requires 100% of manufacturer rebates to pass through to the plan. It limits PBM compensation to bona fide service fees with no link to drug prices or volume.

Most of those provisions do not bite until 2028 or 2029.

The law covers plan years beginning on or after 3 August 2028. Calendar-year plans wait until 1 January 2029. PBMs must also give large group health plans detailed drug pricing and claims reports every six months, or quarterly on request. Adam Colborn of the Academy of Managed Care Pharmacy said rebate retention made up about 55% to 60% of PBM revenue in 2019 but only about 10% in 2025. He cited an IPD Analytics analysis. His reading is that market negotiations had already moved much of that money before lawmakers acted.

Reporting is the operational headache. Colborn said plans and PBMs face new CAA transparency requirements alongside a pending Department of Labor rule on ERISA reporting. Many comments urged regulators to align the two.

What happens next

The House Oversight Committee set a documents deadline of 6 November, after staff briefings with a 30 October request deadline. The DOL disclosures begin for plan years on or after 1 July 2027. CAA 2026 plan-year provisions start on 3 August 2028, or 1 January 2029 for calendar-year plans.